spinph99

KB Home's KBH short percent of float has fallen 9.88% since its last report. The company recently reported that it has 5.68 million shares sold short , which is 12.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.85 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish. See Also: List of the most shorted stocks KB Home Short Interest Graph (3 Months) As you can see from the chart above the percentage of shares that are sold short for KB Home has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted. Comparing KB Home's Short Interest Against Its Peers Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis. According to Benzinga Pro , KB Home's peer group average for short interest as a percentage of float is 5.55%, which means the company has more short interest than most of its peers. Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it. This article was generated by Benzinga's automated content engine and was reviewed by an editor. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

A two-day High-Level Policy Forum on South Asia’s Agricultural Future: Scaling Up Climate-Smart Agriculture Practices for Sustainable Growth was held on 14 and 15 November in the Maldives, following the 2nd Project Steering Committee meeting on 13 November. The workshop brought together researchers, technical experts, agriculture and extension officers, policymakers and farmers from SAARC member states, including Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka. The forum’s key objective is to support the scaling up Climate-Smart Agriculture (CSA) technologies to ensure sustainable agricultural growth and food security across the region. The event was organised by the Consortium for Scaling-up Climate-Smart Agriculture in South Asia (C-SUCSeS), a joint initiative between the SAARC Agriculture Centre (SAC), International Food Policy Research Institute (IFPRI), the International Fund for Agricultural Development (IFAD) and SAARC Development Fund (SDF), in partnership with the Republic of Maldives Agriculture and Animal Welfare Ministry. In an effort to promote the uptake of CSA practices, the C-SUCSeS project introduced comprehensive training modules, video guides, and materials on ten key CSA technologies, as part of the project activities. These resources were developed with inputs from national focal points and regional experts from across the region and were validated by stakeholders during a workshop hosted by the SAC, IFPRI, and the Bangladesh Agricultural Research Council (BARC) earlier this year. The training modules, including farmer’s guides and facilitator manuals, were officially launched by Dr. Aishath Rameela during the forum. Maldives Agriculture and Animal Welfare Minister Dr. Aishath Rameela graced the event as the Chief Guest for the inauguration ceremony. In her address, Dr. Rameela highlighted the importance of cross-country collaboration in addressing the climate impacts on agriculture. “This high-level policy forum offers a unique platform to align our strategies and policies for the future of climate-smart agriculture across South Asia. By working together, we aim to build a resilient agricultural sector that adapts to changing climates, ensures food security, and creates economic opportunities for our people,” said Dr. Rameela. She further emphasised the need for shared learning and evidence-based practices to empower smallholder farmers, who are the most vulnerable to climate change impacts. “By investing in resilient crop varieties, efficient water management practices, and sustainable soil management, we can foster a more productive and climate-resilient agricultural system,” she added. Agriculture and Animal Welfare State Minister Ahmed Hassan Didi also underscored the importance of fostering regional cooperation. “By encouraging policy alignment and fostering dialogue, we can build resilient agricultural ecosystems that support growth, food security, and sustainability,” he said. IFPRI Director – South Asia Dr. Shahidur Rashid stated that, South Asia is one of the most climate-vulnerable regions, and while resilience is critical, it has its limits. “We need to work together to find solutions. Our research outputs must be rigorous, relevant, and timely to make a tangible difference,” he emphasised. SAARC Agriculture Centre Director Dr. Harunur Rashid, highlighted the need for a paradigm shift in agricultural programming. “There is a pressing need to develop sustainable agricultural practices that address farmers’ needs, market access issues, and promote regional cooperation,” he noted, stressing that numerous CSA technologies have been tested and prioritised across the region. IFAD Lead Regional Economist – Asia and the Pacific Region Abdelkarim Sma echoed these sentiments, noting that CSA is now a necessity, not an option. “The C-SUCSeS consortium aims to move beyond small-scale interventions to large-scale solutions that can be deployed effectively across the region,” he said. The event brought attention to the crucial role of cross-sectoral collaboration between governments, research institutions, and the private sector. A central theme discussed was the need to empower smallholder farmers, particularly women, by promoting the uptake of CSA technologies to mitigate food insecurity and poverty. The Policy Forum discussed key topics such as: Creating a conducive policy environment for scaling up CSA in South Asia; future directions for transforming agriculture in the region; the role of emerging technologies and big data in advancing CSA and; innovation hubs and agri-tech startups. Participants emphasised the importance of targeted actions to empower farmers, especially small holders and women farmers, and promote sustainable agricultural practices across South Asia. Through this collaboration, the C-SUCSeS initiative seeks to build a resilient agricultural system capable of addressing the challenges posed by climate change and ensuring long-term food security for the region. Other key delegates attending the event included Maldives Agriculture and Animal Welfare Ministry Department of Agriculture Director General Hussain Faisal, Indian Council of Agricultural Research-Central Research Institute for Dryland Agriculture (ICAR-CRIDA) Director and C-SUCSeS Project Steering Committee Chairperson Dr. V.K. Singh, and SAARC Agriculture Centre Governing Body Chairperson Ali Amir., /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended . "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. As of , the Company had in cash and cash equivalents. As of , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on . During the year ended , the Company received net proceeds of from the issuance of equity. The Company expects to raise additional capital to support operations. R&D expenses were for the full year ended , compared to for the full year ended . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. G&A expenses were for the full year ended , compared to for the full year ended . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. For the full year ended , stock-based compensation expense was as compared to for the prior year. The increase of is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was during the year ended , compared to for the year ended , as the plan was initiated in . For the years ended and 2023, stock-based compensation expense also includes and , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss was , or per share for the year ended , compared to a net loss of , or per share for the year ended , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of offset by a decrease of in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit . This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at , including in Citius Pharma's Annual Report on Form 10-K for the year ended , filed with the SEC on , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. 908-967-6677 x113 STiR-communications -- Financial Tables Follow –

Penn State has won a closely watched trademark fight over an online retailer’s use of its vintage sports logos and images. A Pennsylvania jury awarded Penn State $28,000 in damages on Wednesday over products made and sold by Vintage Brand and Sportswear Inc., two firms co-founded by former minor league baseball player Chad Hartvigson. Penn State accused them of selling “counterfeit” clothing and accessories, while the defendants said their website makes clear they are not affiliated with the university. At least a dozen other schools have sued the defendants on similar grounds, including Purdue, Stanford and UCLA, Penn State said in its 2021 lawsuit. However, the Penn State case was the first to go to trial and seen by some as a test case in the sports merchandising industry. “It addresses an important issue with trademark law — whether or not the mark owner is able to prevent third parties from using its marks on T-shirts and paraphernalia without permission,” said Tiffany Gehrke, a trademark lawyer in Chicago who was not involved in the case. The verdict, she said, maintains the status quo, while a victory for Vintage Brand “could have shaken things up.” It followed a six-day trial in federal court in Williamsport, Pennsylvania, overseen by Chief U.S. District Judge Matthew W. Brann. It was not immediately clear if the defendants planned to appeal. Phone and email messages left with their lawyers on Thursday were not immediately returned. Penn State, in a statement, called its trademarks “critical” to the school’s brand, and said it was grateful for the verdict. “The university appreciates this result as it relates to the many hundreds of licensees with whom the university works and who go through the appropriate processes to use Penn State’s trademarks,” the statement said. Penn State, founded in 1855, adopted the Nittany Lion as its mascot in 1904 and has been using various images of the animal, along with the school’s seal and other logos, for decades, the lawsuit said. The school now has more than 100,000 students at 24 campuses. Never miss a moment with the WHYY Listen App! Play, pause, and rewind the live radio stream, access on-demand audio features, and dive into podcasts from both local and national sources. WHYY is your source for fact-based, in-depth journalism and information. As a nonprofit organization, we rely on financial support from readers like you. Please give today.

UMaine breaks ground on new soccer, track and basketball facilities